


1. Introduction

- Shigellosis, bacillary dysentery spread through faecal-oral contact, was traditionally travel-associated in England but sexual transmission of *Shigella flexneri* and *Shigella sonnei* among gay, bisexual and other men who have sex with men (MSM) is now common.
- When needed, ciprofloxacin is the primary treatment for shigellosis, with azithromycin and ceftriaxone second line.
- Emergence of extensively drug-resistant (XDR) *S. sonnei* in September 2021 harbouring plasmid-encoded *bla*_{CTX-M-27}, conferring resistance to ceftriaxone, raised concerns over further spread of this gene.
- Using national surveillance, we identified and characterised *S. flexneri* harbouring *bla*_{CTX-M-27} in England.



Shigella awareness Social Media campaign post; a joint campaign between UKHSA (formerly PHE) and HIV Prevention England (HPE), aiming to raise awareness of shigellosis among gay and bisexual men in 2021. Available through the [HPE website](#).

2. Methods

- Shigella* spp. isolates referred to the Gastrointestinal Bacterial Reference Unit at UKHSA undergo whole genome sequencing, enabling antimicrobial resistance (AMR) determination using genetic markers. Isolates were defined as multidrug-resistant (MDR) when resistant to over three of the antimicrobial classes fluoroquinolones, β -lactam antibiotics, tetracyclines, 3rd generation cephalosporins, trimethoprim, aminoglycosides, macrolides, and sulphonamides; and XDR when resistant to all but two.
- S. flexneri* isolates, referred between 01 September 2015 and 12 June 2022, harbouring *bla*_{CTX-M-27} were identified and phylogenetically characterised.
- Long-read sequencing elucidated the genomic location of *bla*_{CTX-M-27}
- Laboratory data, integrated with available demographic and clinical information from patient questionnaires, was summarised using descriptive statistics.





Figure: (A) *S. flexneri* serotype 2a diagnoses by presence or absence of *bla*_{CTX-M-27} and specimen date in England, September 2015 to June 2022. **(B)** Comparison of IncFII plasmids isolated from seven *S. flexneri* 2a cases (reference included) in England compared with an IncFII plasmid from a case of the XDR *S. sonnei* Clade 5 (SRR18254054).

3. Results

- A sustained increase in *S. flexneri* 2a harbouring *bla*_{CTX-M-27} (n=26) occurred from September 2021, having been sporadically reported only 4 times in the preceding six years (alongside sporadic occurrences of other serotypes 1c (n=3), 1a (n=2) and 3a (n=2)) (Figure A).
- Phylogenetic analysis characterised separate *bla*_{CTX-M-27} acquisition events within *S. flexneri* 2a, establishing an XDR (n=8) and a MDR (n=18) cluster.
- All 26 cases were adult men, and of those with a patient questionnaire, most identified as MSM (77%; 10/13). Antimicrobial treatment was received for 54% (7/13) of individuals, and 31% (4/13) were hospitalised.
- The *bla*_{CTX-M-27} genetic marker was encoded on an IncFII plasmid; comparison to the XDR *S. sonnei* outbreak plasmid showed high similarity, with 82% and 99% nucleotide similarity for the XDR (Cluster 1) and MDR (Cluster 2) plasmids, respectively (Figure B).



4. Conclusions

- We report emergence of XDR and MDR *S. flexneri* 2a clusters harbouring *bla*_{CTX-M-27}, among MSM in England.
- Epidemiological and plasmid similarities with the XDR *S. sonnei* outbreak support horizontal acquisition events, emphasising the importance of mobilisable AMR and need for genomic-based surveillance and research.